PMC:7417114 / 56937-57222 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T278","span":{"begin":41,"end":45},"obj":"Body_part"}],"attributes":[{"id":"A278","pred":"fma_id","subj":"T278","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"Pulmonary toxicity, such as interstitial lung disease, is a rare side effect associated with ALK inhibitors; most can be managed efficiently by lowering doses or interrupting treatment; in a clinical trial, pneumonitis was reported in 4% of ceritinib-treated patients (238) (239) (240)"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T86","span":{"begin":41,"end":45},"obj":"Body_part"}],"attributes":[{"id":"A86","pred":"uberon_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Pulmonary toxicity, such as interstitial lung disease, is a rare side effect associated with ALK inhibitors; most can be managed efficiently by lowering doses or interrupting treatment; in a clinical trial, pneumonitis was reported in 4% of ceritinib-treated patients (238) (239) (240)"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T536","span":{"begin":28,"end":53},"obj":"Disease"},{"id":"T537","span":{"begin":41,"end":53},"obj":"Disease"},{"id":"T538","span":{"begin":207,"end":218},"obj":"Disease"}],"attributes":[{"id":"A536","pred":"mondo_id","subj":"T536","obj":"http://purl.obolibrary.org/obo/MONDO_0015925"},{"id":"A537","pred":"mondo_id","subj":"T537","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A538","pred":"mondo_id","subj":"T538","obj":"http://purl.obolibrary.org/obo/MONDO_0043905"}],"text":"Pulmonary toxicity, such as interstitial lung disease, is a rare side effect associated with ALK inhibitors; most can be managed efficiently by lowering doses or interrupting treatment; in a clinical trial, pneumonitis was reported in 4% of ceritinib-treated patients (238) (239) (240)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T635","span":{"begin":41,"end":45},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T636","span":{"begin":41,"end":45},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T637","span":{"begin":58,"end":59},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T638","span":{"begin":189,"end":190},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Pulmonary toxicity, such as interstitial lung disease, is a rare side effect associated with ALK inhibitors; most can be managed efficiently by lowering doses or interrupting treatment; in a clinical trial, pneumonitis was reported in 4% of ceritinib-treated patients (238) (239) (240)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T61525","span":{"begin":93,"end":107},"obj":"Chemical"},{"id":"T96071","span":{"begin":97,"end":107},"obj":"Chemical"},{"id":"T37503","span":{"begin":241,"end":250},"obj":"Chemical"}],"attributes":[{"id":"A94124","pred":"chebi_id","subj":"T61525","obj":"http://purl.obolibrary.org/obo/CHEBI_62434"},{"id":"A41288","pred":"chebi_id","subj":"T96071","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A10654","pred":"chebi_id","subj":"T37503","obj":"http://purl.obolibrary.org/obo/CHEBI_78432"}],"text":"Pulmonary toxicity, such as interstitial lung disease, is a rare side effect associated with ALK inhibitors; most can be managed efficiently by lowering doses or interrupting treatment; in a clinical trial, pneumonitis was reported in 4% of ceritinib-treated patients (238) (239) (240)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1533","span":{"begin":93,"end":96},"obj":"Gene"},{"id":"1584","span":{"begin":259,"end":267},"obj":"Species"}],"attributes":[{"id":"A1533","pred":"tao:has_database_id","subj":"1533","obj":"Gene:238"},{"id":"A1584","pred":"tao:has_database_id","subj":"1584","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Pulmonary toxicity, such as interstitial lung disease, is a rare side effect associated with ALK inhibitors; most can be managed efficiently by lowering doses or interrupting treatment; in a clinical trial, pneumonitis was reported in 4% of ceritinib-treated patients (238) (239) (240)"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T163","span":{"begin":28,"end":53},"obj":"Phenotype"}],"attributes":[{"id":"A163","pred":"hp_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/HP_0006530"}],"text":"Pulmonary toxicity, such as interstitial lung disease, is a rare side effect associated with ALK inhibitors; most can be managed efficiently by lowering doses or interrupting treatment; in a clinical trial, pneumonitis was reported in 4% of ceritinib-treated patients (238) (239) (240)"}

{"project":"2_test","denotations":[{"id":"32778962-29174221-84130751","span":{"begin":269,"end":272},"obj":"29174221"},{"id":"32778962-30771874-84130752","span":{"begin":275,"end":278},"obj":"30771874"},{"id":"32778962-31019956-84130753","span":{"begin":281,"end":284},"obj":"31019956"}],"text":"Pulmonary toxicity, such as interstitial lung disease, is a rare side effect associated with ALK inhibitors; most can be managed efficiently by lowering doses or interrupting treatment; in a clinical trial, pneumonitis was reported in 4% of ceritinib-treated patients (238) (239) (240)"}